多重抗藥性結核病

Translated title of the contribution: Multidrug-Resistant Tuberculosis

許 翰琳(Han-Lin Hsu), 白 冠壬(Kuan-Jen Bai), 林 賢君(Shian-Jiun Lin), 李 俊年(Chun-Nin Lee), 余 明治(Ming-Chih Yu)

Research output: Contribution to journalReview article

Abstract

Multidrug-resistant tuberculosis (MDR-TB) is defined by bacillary resistant to at least isoniazid and rifampicin in vitro. Although a great diversity of reasons accounting for MDR-TB, poor treatment adherence of patient or inappropriate prescription of physicians are still the major causes. Implementation of DOTS (directly observed therapy, short-course) could decrease incidence of MDR-TB. For MDR-TB, prevention is best strategy. Besides, implantation of DOTS-plus also could increase cure rate. To build efficacious framework system for managing tuberculosis is an important issue to prevent and treat MDR-TB.
Original languageTraditional Chinese
Pages (from-to)524-531
Number of pages8
JournalJournal of Internal Medicine of Taiwan
Volume20
Issue number6
DOIs
Publication statusPublished - 2009

Fingerprint

Multidrug-Resistant Tuberculosis
Directly Observed Therapy
Inappropriate Prescribing
Isoniazid
Rifampin
Patient Compliance
Tuberculosis
Physicians
Incidence

Keywords

  • 多重抗藥性結核病
  • 都治計畫
  • 進階都治計劃
  • Multidrug-resistant tuberculosis
  • Directly observed therapy, short-course
  • DOTS
  • DOTS-Plus

Cite this

多重抗藥性結核病. / 許翰琳(Han-Lin Hsu); 白冠壬(Kuan-Jen Bai); 林賢君(Shian-Jiun Lin); 李俊年(Chun-Nin Lee); 余明治(Ming-Chih Yu).

In: Journal of Internal Medicine of Taiwan, Vol. 20, No. 6, 2009, p. 524-531.

Research output: Contribution to journalReview article

許翰琳(Han-Lin Hsu) ; 白冠壬(Kuan-Jen Bai) ; 林賢君(Shian-Jiun Lin) ; 李俊年(Chun-Nin Lee) ; 余明治(Ming-Chih Yu). / 多重抗藥性結核病. In: Journal of Internal Medicine of Taiwan. 2009 ; Vol. 20, No. 6. pp. 524-531.
@article{2514129beea9434e8f35b084149a59c8,
title = "多重抗藥性結核病",
abstract = "多重抗藥性結核病(multidrug-resistant tuberculosis)是指罹患至少對最重要的兩種抗結核藥物isoniazid及rifampicin抗藥的結核菌株之結核病。造成多重抗藥性結核病的原因很多,但最常見的原因多爲病人服藥順從性不佳或醫師不適當之治療療程。藉由短程直接觀察療法「都治計畫」(directly observed therapy, short-course; DOTS)的介入,能減少多重抗藥性結核病的產生。而對於多重抗藥性結核病而言,預防永遠是最好的策略。另外藉由「進階都治計劃」(DOTS-Plus)的介入,以期增加多重抗藥性結核病的治癒率。經由建構有效率的結核病防治體系,是預防及治療多重抗藥性結核病的重要策略。",
keywords = "多重抗藥性結核病, 都治計畫, 進階都治計劃, Multidrug-resistant tuberculosis, Directly observed therapy, short-course, DOTS, DOTS-Plus, 多重抗藥性結核病, 都治計畫, 進階都治計劃 , Multidrug-resistant tuberculosis, Directly observed therapy, short-course, DOTS , DOTS-Plus",
author = "許, {翰琳(Han-Lin Hsu)} and 白, {冠壬(Kuan-Jen Bai)} and 林, {賢君(Shian-Jiun Lin)} and 李, {俊年(Chun-Nin Lee)} and 余, {明治(Ming-Chih Yu)}",
year = "2009",
doi = "10.6314/JIMT.2009.20(6).07",
language = "繁體中文",
volume = "20",
pages = "524--531",
journal = "Journal of Internal Medicine of Taiwan",
issn = "1016-7390",
publisher = "臺灣內科醫學會",
number = "6",

}

TY - JOUR

T1 - 多重抗藥性結核病

AU - 許, 翰琳(Han-Lin Hsu)

AU - 白, 冠壬(Kuan-Jen Bai)

AU - 林, 賢君(Shian-Jiun Lin)

AU - 李, 俊年(Chun-Nin Lee)

AU - 余, 明治(Ming-Chih Yu)

PY - 2009

Y1 - 2009

N2 - 多重抗藥性結核病(multidrug-resistant tuberculosis)是指罹患至少對最重要的兩種抗結核藥物isoniazid及rifampicin抗藥的結核菌株之結核病。造成多重抗藥性結核病的原因很多,但最常見的原因多爲病人服藥順從性不佳或醫師不適當之治療療程。藉由短程直接觀察療法「都治計畫」(directly observed therapy, short-course; DOTS)的介入,能減少多重抗藥性結核病的產生。而對於多重抗藥性結核病而言,預防永遠是最好的策略。另外藉由「進階都治計劃」(DOTS-Plus)的介入,以期增加多重抗藥性結核病的治癒率。經由建構有效率的結核病防治體系,是預防及治療多重抗藥性結核病的重要策略。

AB - 多重抗藥性結核病(multidrug-resistant tuberculosis)是指罹患至少對最重要的兩種抗結核藥物isoniazid及rifampicin抗藥的結核菌株之結核病。造成多重抗藥性結核病的原因很多,但最常見的原因多爲病人服藥順從性不佳或醫師不適當之治療療程。藉由短程直接觀察療法「都治計畫」(directly observed therapy, short-course; DOTS)的介入,能減少多重抗藥性結核病的產生。而對於多重抗藥性結核病而言,預防永遠是最好的策略。另外藉由「進階都治計劃」(DOTS-Plus)的介入,以期增加多重抗藥性結核病的治癒率。經由建構有效率的結核病防治體系,是預防及治療多重抗藥性結核病的重要策略。

KW - 多重抗藥性結核病

KW - 都治計畫

KW - 進階都治計劃

KW - Multidrug-resistant tuberculosis

KW - Directly observed therapy, short-course

KW - DOTS

KW - DOTS-Plus

KW - 多重抗藥性結核病

KW - 都治計畫

KW - 進階都治計劃

KW - Multidrug-resistant tuberculosis

KW - Directly observed therapy, short-course

KW - DOTS

KW - DOTS-Plus

UR - http://www.airitilibrary.com/Publication/alDetailedMesh?DocID=10167390-200912-200912290010-200912290010-524-531

U2 - 10.6314/JIMT.2009.20(6).07

DO - 10.6314/JIMT.2009.20(6).07

M3 - 回顧型文獻

VL - 20

SP - 524

EP - 531

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

SN - 1016-7390

IS - 6

ER -